loading
Solid Biosciences Inc stock is traded at $4.72, with a volume of 7.02M. It is down -1.87% in the last 24 hours and up +55.26% over the past month. Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$4.81
Open:
$4.77
24h Volume:
7.02M
Relative Volume:
4.57
Market Cap:
$374.40M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.5526
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-1.46%
1M Performance:
+55.26%
6M Performance:
+11.32%
1Y Performance:
-17.77%
1-Day Range:
Value
$4.64
$4.85
1-Week Range:
Value
$4.39
$5.20
52-Week Range:
Value
$2.41
$10.37

Solid Biosciences Inc Stock (SLDB) Company Profile

Name
Name
Solid Biosciences Inc
Name
Phone
617-337-4680
Name
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Name
Employee
100
Name
Twitter
@SolidBioDMD
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
SLDB's Discussions on Twitter

Compare SLDB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SLDB
Solid Biosciences Inc
4.72 374.40M 14.79M -102.44M -91.73M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-25 Initiated Truist Buy
Dec-13-24 Initiated Wedbush Outperform
Dec-10-24 Initiated JMP Securities Mkt Outperform
Jul-15-24 Upgrade JP Morgan Neutral → Overweight
Jun-24-24 Upgrade Leerink Partners Market Perform → Outperform
May-31-24 Resumed Piper Sandler Overweight
Mar-28-24 Initiated William Blair Outperform
Mar-15-24 Initiated Citigroup Buy
Mar-14-24 Upgrade Piper Sandler Neutral → Overweight
Dec-08-23 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated Piper Sandler Neutral
May-27-21 Initiated Jefferies Buy
Mar-16-21 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-09-21 Initiated Barclays Overweight
Jan-08-21 Upgrade Credit Suisse Underperform → Neutral
Jul-28-20 Downgrade SVB Leerink Outperform → Mkt Perform
May-07-20 Downgrade Evercore ISI Outperform → In-line
Oct-11-19 Initiated Evercore ISI Outperform
Aug-29-19 Downgrade Citigroup Neutral → Sell
Aug-19-19 Upgrade SVB Leerink Mkt Perform → Outperform
Aug-16-19 Upgrade Chardan Capital Markets Neutral → Buy
May-14-19 Downgrade Credit Suisse Neutral → Underperform
May-14-19 Downgrade Goldman Neutral → Sell
Feb-08-19 Upgrade Citigroup Sell → Neutral
Feb-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18 Initiated Citigroup Sell
Sep-06-18 Initiated Credit Suisse Neutral
View All

Solid Biosciences Inc Stock (SLDB) Latest News

pulisher
Jun 18, 2025

Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces key catalysts - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target | SLDB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Solid Biosciences (SLDB) Gains Confidence Amid Safety Concerns w - GuruFocus

Jun 17, 2025
pulisher
Jun 14, 2025

Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid DMD competition - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Solid Biosciences Approves Equity Plan Amendment at Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 06, 2025

Solid Biosciences (SLDB) Maintains Market Outperform Rating | SL - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Transcript : Solid Biosciences Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com

Jun 06, 2025
pulisher
Jun 05, 2025

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 03, 2025

Solid Biosciences (SLDB) Announces Stock Grants Under Inducement Plan | SLDB Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 03, 2025
pulisher
Jun 03, 2025

Solid Biosciences Awards Strategic RSU Grants: New Hires Receive 34,550 Shares Under Nasdaq Compensation Rule - Stock Titan

Jun 03, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Northern Trust Corp Has $676,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 31, 2025
pulisher
May 30, 2025

Solid Biosciences Reports Increased Loss Amid R&D Expansion - TipRanks

May 30, 2025
pulisher
May 30, 2025

BNP Paribas Financial Markets Acquires New Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 30, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Buys Shares of 51,972 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 29, 2025
pulisher
May 28, 2025

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 27, 2025
pulisher
May 26, 2025

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Research Analysts Set Expectations for SLDB FY2025 Earnings - Defense World

May 26, 2025
pulisher
May 22, 2025

Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fi - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fitzgerald | SLDB Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

Solid Biosciences (NASDAQ:SLDB) Given New $15.00 Price Target at Chardan Capital - Defense World

May 20, 2025
pulisher
May 19, 2025

Solid Biosciences (SLDB) Maintains Buy Rating Amid Revised Price Target | SLDB Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Q1 Earnings Forecast for SLDB Issued By William Blair - Defense World

May 19, 2025
pulisher
May 18, 2025

Wedbush Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World

May 18, 2025
pulisher
May 17, 2025

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Target Price Updated by Wedbush Analyst - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks

May 16, 2025
pulisher
May 16, 2025

Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks

May 15, 2025
pulisher
May 15, 2025

SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Form 424B5 Solid Biosciences Inc. - StreetInsider

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Provides Business Update and Financial Results for Q1 2025, Advances Gene Therapy Programs for Duchenne Muscular Dystrophy, Friedreich's Ataxia, and CPVT - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

May 15, 2025

Solid Biosciences Inc Stock (SLDB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Solid Biosciences Inc Stock (SLDB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Bain Capital Life Sciences Inv
10% Owner
Feb 19 '25
Buy
4.03
1,000,000
4,030,000
5,034,582
PERCEPTIVE ADVISORS LLC
Director
Feb 19 '25
Buy
4.03
5,000,000
20,150,000
11,833,539
Adage Capital Management, L.P.
10% Owner
Feb 18 '25
Buy
7.56
252,545
1,909,240
4,248,084
Hanrahan Jessie
Chief Regulatory Officer
Feb 14 '25
Sale
3.96
3,079
12,193
19,281
Brooks Gabriel
Chief Medical Officer
Feb 14 '25
Sale
3.96
3,256
12,894
22,812
Tan Kevin
CFO & Treasurer
Feb 14 '25
Sale
3.96
3,164
12,529
32,250
Howton David T
Chief Operating Officer
Feb 14 '25
Sale
3.96
5,561
22,022
24,789
Herzich Paul
Chief Technology Officer
Feb 14 '25
Sale
3.96
2,688
10,644
18,388
Cumbo Alexander
President and CEO
Feb 14 '25
Sale
3.96
11,365
45,005
60,717
Ganot Ilan
Director
Feb 14 '25
Sale
3.96
1,711
6,776
14,839
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Cap:     |  Volume (24h):